Investigating HIV-1 Resistance to CCR5 Antagonist Maraviroc for the Design of New Prevention Strategies

被引：0

作者：

Flynn, Jacqueline K. ^{[1
,2
]}

Roche, Michael ^{[1
,2
]}

Paukovics, Geza ^{[1
]}

Salimi, Hamid ^{[1
,2
]}

Duncan, Renee C. ^{[1
]}

Moore, Miranda S. ^{[1
]}

Ellet, Anne ^{[1
]}

Gray, Lachlan R. ^{[1
,2
]}

Jubb, Becky ^{[3
]}

Westby, Mike ^{[3
]}

Purcell, Damian F. J. ^{[4
]}

Lewin, Sharon R. ^{[1
,2
]}

Lee, Benhur ^{[5
]}

Payne, Richard J. ^{[6
]}

Churchill, Melissa J. ^{[1
,2
]}

Gorry, Paul R. ^{[1
,2
]}

机构：

[1] Burnet Inst, Melbourne, Vic, Australia

[2] Monash Univ, Melbourne, Vic 3004, Australia

[3] Pfizer Global Res & Dev, Sandwich, Kent, England

[4] Univ Melbourne, Melbourne, Vic, Australia

[5] Univ Calif Los Angeles, Los Angeles, CA USA

[6] Univ Sydney, Sydney, NSW 2006, Australia

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2014年 / 30卷

关键词：

D O I：

10.1089/aid.2014.5459.abstract

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P35.02

引用

页码：A212 / A212

页数：1

共 50 条

[21] Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc
Latinovic, Olga
Schneider, Kate
Szmacinski, Henryk
Lakowicz, Joseph R.
Heredia, Alonso
Redfield, Robert R.
[J]. ANTIVIRAL RESEARCH, 2014, 112 : 80 - 90
[22] Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
Lorenzen, Thore
[J]. HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2010, 2 : 151 - 156
[23] Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay
van der Ryst, Elna
Heera, Jayvant
Demarest, James
Knirsch, Charles
[J]. COMPANION DIAGNOSTICS: FROM BIOMARKER IDENTIFICATION TO MARKET ENTRY, 2015, 1346 : 7 - 17
[24] Analysis of the prevalence of CCR5 coreceptor antagonist resistance mutations among HIV-1 variants in Russia
Vasilyev, A. V.
Kazennova, E. V.
Bobkova, M. R.
[J]. VOPROSY VIRUSOLOGII, 2011, 56 (03) : 32 - 37
[25] Study of intracellular and immunomodulant effects of CCR5 Antagonist Maraviroc
Sauzullo, I.
Mengoni, F.
Rossi, R.
Celardo, I.
Ghibelli, L.
Lichtner, M.
Massetti, A. P.
Mastroianni, C. M.
Vullo, V.
[J]. INFECTION, 2010, 38 : 92 - 93
[26] The promise of CCR5 antagonists as new therapies for HIV-1
Repik, Alexander
Richards, Kathryn H.
Clapham, Paul R.
[J]. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (02) : 130 - 139
[27] Preparation and Activities of Macromolecule Conjugates of the CCR5 Antagonist Maraviroc
Asano, Shigehiro
Gavrilyuk, Julia
Burton, Dennis R.
Barbas, Carlos F., III
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (02): : 133 - 137
[28] Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc
Price, David A.
Armour, Duncan
de Groot, Marcel
Leishman, Derek
Napier, Carolyn
Perros, Manos
Stammen, Blanda L.
Wood, Anthony
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (17) : 4633 - 4637
[29] CCR5 HIV-1 vertical transmission
Shearer, WT
Kalish, LA
Zimmerman, PA
[J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02): : 180 - 181
[30] CCR5 inhibitors in HIV-1 therapy
Dorr, Patrick
Perros, Manos
[J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361

← 1 2 3 4 5 →